S. 27, The Preserve Access to Affordable Generics Act (4 wiki edits)
- This item is from the 112th Congress (2011-2012) and is no longer current. Comments, voting, and wiki editing have been disabled, and the cost/savings estimate has been frozen.
- This bill, or a similar bill, was reintroduced in the current Congress as S. 214, The Preserve Access to Affordable Generics Act.
S. 27 would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.